IL181754A0 - Compositions and methods relating to novel compounds and targets thereof - Google Patents
Compositions and methods relating to novel compounds and targets thereofInfo
- Publication number
- IL181754A0 IL181754A0 IL181754A IL18175407A IL181754A0 IL 181754 A0 IL181754 A0 IL 181754A0 IL 181754 A IL181754 A IL 181754A IL 18175407 A IL18175407 A IL 18175407A IL 181754 A0 IL181754 A0 IL 181754A0
- Authority
- IL
- Israel
- Prior art keywords
- targets
- compositions
- novel compounds
- methods relating
- relating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/935,333 US20050113460A1 (en) | 1999-04-30 | 2004-09-07 | Compositions and methods relating to novel compounds and targets thereof |
PCT/US2005/031942 WO2006029245A2 (en) | 2004-09-07 | 2005-09-07 | Compositions and methods relating to novel compounds and targets thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IL181754A0 true IL181754A0 (en) | 2007-07-04 |
Family
ID=36036988
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL181754A IL181754A0 (en) | 2004-09-07 | 2007-03-06 | Compositions and methods relating to novel compounds and targets thereof |
IL218524A IL218524A0 (en) | 2004-09-07 | 2012-03-07 | Compositions and methods relating to novel compounds and targets thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL218524A IL218524A0 (en) | 2004-09-07 | 2012-03-07 | Compositions and methods relating to novel compounds and targets thereof |
Country Status (8)
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60007960T2 (de) | 1999-04-30 | 2004-10-21 | Univ Michigan Ann Arbor | Therapeutische Anwendungen von pro-apoptotischen Benzodiazepinen |
US7276348B2 (en) * | 1999-04-30 | 2007-10-02 | Regents Of The University Of Michigan | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof |
US20050113460A1 (en) * | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20040176358A1 (en) * | 1999-04-30 | 2004-09-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20060025388A1 (en) | 1999-04-30 | 2006-02-02 | Glick Gary D | Compositions and methods relating to novel compounds and targets thereof |
US7144880B2 (en) * | 1999-04-30 | 2006-12-05 | Regents Of The University Of Michigan | Compositions relating to novel compounds and targets thereof |
JP2007514759A (ja) * | 2003-12-19 | 2007-06-07 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
US8092549B2 (en) | 2004-09-24 | 2012-01-10 | The Invention Science Fund I, Llc | Ciliated stent-like-system |
US8361013B2 (en) | 2004-04-19 | 2013-01-29 | The Invention Science Fund I, Llc | Telescoping perfusion management system |
US8337482B2 (en) * | 2004-04-19 | 2012-12-25 | The Invention Science Fund I, Llc | System for perfusion management |
US7998060B2 (en) | 2004-04-19 | 2011-08-16 | The Invention Science Fund I, Llc | Lumen-traveling delivery device |
US9011329B2 (en) | 2004-04-19 | 2015-04-21 | Searete Llc | Lumenally-active device |
US7857767B2 (en) * | 2004-04-19 | 2010-12-28 | Invention Science Fund I, Llc | Lumen-traveling device |
US7850676B2 (en) | 2004-04-19 | 2010-12-14 | The Invention Science Fund I, Llc | System with a reservoir for perfusion management |
US8019413B2 (en) | 2007-03-19 | 2011-09-13 | The Invention Science Fund I, Llc | Lumen-traveling biological interface device and method of use |
US9801527B2 (en) | 2004-04-19 | 2017-10-31 | Gearbox, Llc | Lumen-traveling biological interface device |
US8353896B2 (en) | 2004-04-19 | 2013-01-15 | The Invention Science Fund I, Llc | Controllable release nasal system |
WO2005105788A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
US20050272723A1 (en) * | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
WO2006023931A2 (en) * | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US7638624B2 (en) * | 2005-01-03 | 2009-12-29 | The Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and derivatives |
JP2008545757A (ja) * | 2005-06-01 | 2008-12-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 溶媒和されていないベンゾジアゼピン組成物および方法 |
US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20070105844A1 (en) * | 2005-10-26 | 2007-05-10 | Regents Of The University Of Michigan | Therapeutic compositions and methods |
WO2007050587A2 (en) * | 2005-10-26 | 2007-05-03 | The Regents Of The University Of Michigan | Therapeutic compositions and methods |
AU2006308655B2 (en) | 2005-11-01 | 2010-09-23 | The Regents Of The University Of Michigan | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties |
US20120035438A1 (en) | 2006-04-12 | 2012-02-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Path selection by a lumen traveling device in a body tub tree based on previous path |
US9220917B2 (en) | 2006-04-12 | 2015-12-29 | The Invention Science Fund I, Llc | Systems for autofluorescent imaging and target ablation |
US7759338B2 (en) * | 2006-04-27 | 2010-07-20 | The Regents Of The University Of Michigan | Soluble 1,4 benzodiazepine compounds and stable salts thereof |
EP2418206A3 (en) | 2006-06-09 | 2012-06-27 | The Regents of the University of Michigan | Benzodiazepine derivatives useful in the treatment of autoimmune disorders |
JP2010505961A (ja) * | 2006-10-09 | 2010-02-25 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
BRPI0808653A2 (pt) | 2007-03-09 | 2014-08-19 | Univ Michigan | Composições e métodos referindo-se a novos compostos e alvos dos mesmos. |
CN101855203B (zh) | 2007-09-14 | 2014-03-19 | 密执安州立大学董事会 | F1f0-atp合成酶抑制剂以及相关的方法 |
JP5539212B2 (ja) | 2007-11-06 | 2014-07-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 皮膚症状の治療に有用なベンゾジアゼピノン化合物 |
US8598150B1 (en) | 2008-04-02 | 2013-12-03 | Jonathan R. Brestoff | Composition and method for affecting obesity and related conditions |
US8987245B2 (en) | 2008-04-02 | 2015-03-24 | Jonathan R. Brestoff Parker | Composition and method for affecting obesity and related conditions |
WO2010030891A2 (en) | 2008-09-11 | 2010-03-18 | The Regents Of The University Of Michigan | Aryl guanidine f1f0-atpase inhibitors and related methods |
WO2010121164A2 (en) | 2009-04-17 | 2010-10-21 | The Regents Of The University Of Michigan | 1,4-benzodiazepinone compounds and their use in treating cancer |
JP2013505258A (ja) | 2009-09-18 | 2013-02-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ベンゾジアゼピノン化合物およびそれを使用する治療方法 |
CA2915237C (en) | 2009-11-17 | 2017-10-10 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
WO2011062766A2 (en) | 2009-11-17 | 2011-05-26 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2457405A (en) * | 1945-09-25 | 1948-12-28 | Monsanto Chemicals | Halo nitroparaffin modified aminoplasts |
US3261828A (en) * | 1962-10-04 | 1966-07-19 | Hoffmann La Roche | 3h-1,4-benzodiazepine-2,5(1h,4h)-dione compounds |
US3374264A (en) * | 1962-10-04 | 1968-03-19 | Hoffmann La Roche | N-haloacetyl-anthranilic acids and esters |
US3415814A (en) * | 1966-09-28 | 1968-12-10 | Sterling Drug Inc | 4-(cyclopropylmethyl)-3h-1,4-benzodiazepine-2,5(1h,4h)-dione |
US3384635A (en) * | 1966-09-28 | 1968-05-21 | Sterling Drug Inc | 1, 4-benzodiazepine derivatives |
USRE30293E (en) * | 1969-03-18 | 1980-06-03 | Knoll A.G. | Process for preparing 1,5-benzodiazepine-2-ones |
US4108852A (en) * | 1969-03-18 | 1978-08-22 | Knoll Ag. | Process for preparing 1,5-benzodiazepine-2-ones |
GB1324469A (en) * | 1970-10-28 | 1973-07-25 | Knoll Ag | Derivatives of benzodiazepines |
ZA7464B (en) * | 1973-01-16 | 1974-11-27 | J Voorhees | Treatment of proliferating skin diseases with papavine alkaloids |
IE38931B1 (en) * | 1973-03-09 | 1978-07-05 | Lipha | Triazolobenzodiazepines |
US4076823A (en) * | 1977-08-18 | 1978-02-28 | E. R. Squibb & Sons, Inc. | Triazolo-2,4-benzodiazepines |
US4495101A (en) * | 1983-04-28 | 1985-01-22 | American Home Products Corporation | Antiinflammatory 5H-tetrazolo (5,1-c)(1,4)benzodiazepine derivatives |
US4551480A (en) * | 1983-06-21 | 1985-11-05 | Stiefel Laboratories, Inc. | Compositions for the treatment of psoriasis |
US4894366A (en) * | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
US4820834A (en) * | 1984-06-26 | 1989-04-11 | Merck & Co., Inc. | Benzodiazepine analogs |
US5004741A (en) * | 1984-06-26 | 1991-04-02 | Merck & Co., Inc. | Methods of antagonizing CCK or gastrin with benzodiazepine analogs |
DE3435974A1 (de) * | 1984-10-01 | 1986-04-10 | Boehringer Ingelheim KG, 6507 Ingelheim | Diazepine enthaltende pharmazeutische zusammensetzungen mit paf-antagonistischer wirkung |
GB8608080D0 (en) * | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4751223A (en) * | 1986-10-14 | 1988-06-14 | Hoechst-Roussel Pharmaceuticals, Inc. | Antiinflammatory and analgesic aminoalkyl tetracyclic benzodiazepines |
US4898861A (en) * | 1987-03-26 | 1990-02-06 | Hoffmann-La Roche Inc. | Method for inhibiting the proliferation of tumor cells |
US5147872A (en) * | 1987-06-09 | 1992-09-15 | Golwyn Daniel H | Treatment of immunologically based disorders, specifically psoriasis |
US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
SE8804074D0 (sv) | 1988-11-10 | 1988-11-10 | Pharmacia Ab | Sensorenhet och dess anvaendning i biosensorsystem |
WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
US5258510A (en) * | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
US5041438A (en) * | 1989-10-30 | 1991-08-20 | Hoffmann-La Roche Inc. | Method for treating retroviral infections with benzodiazepine compounds |
US5324726A (en) * | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
EP0470246B1 (en) | 1990-02-28 | 1995-06-28 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
ATE145208T1 (de) * | 1990-07-06 | 1996-11-15 | Yoshitomi Pharmaceutical | Kondensierte thiophenverbindungen und deren verwendung |
BR9200951A (pt) * | 1991-03-21 | 1992-11-17 | Hoffmann La Roche | Compostos, processo para sua producao,preparacoes farmaceuticas e uso |
JPH07504908A (ja) * | 1992-03-16 | 1995-06-01 | メルク シヤープ エンド ドーム リミテツド | ベンゾジアゼピン誘導体,該誘導体を含有する組成物及び治療におけるその使用 |
US5599352A (en) * | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
US5288514A (en) * | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
GB9307527D0 (en) * | 1993-04-13 | 1993-06-02 | Fujisawa Pharmaceutical Co | New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
US5391566A (en) * | 1993-07-20 | 1995-02-21 | Merck & Co., Inc. | Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives |
US6524832B1 (en) * | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
US5444092A (en) * | 1994-07-20 | 1995-08-22 | Collins; Jerry | Method and composition for treating psoriasis |
WO1996004254A2 (en) * | 1994-07-29 | 1996-02-15 | Fujisawa Pharmaceutical Co., Ltd. | Benzodiazepine derivatives |
CA2195973A1 (en) * | 1994-08-18 | 1996-02-29 | David A. Claremon | N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines |
US5618792A (en) * | 1994-11-21 | 1997-04-08 | Cortech, Inc. | Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase |
AU5752696A (en) * | 1995-05-18 | 1996-11-29 | Regents Of The University Of Michigan, The | Dna binding antibodies |
US5677282A (en) * | 1995-06-07 | 1997-10-14 | Proscript, Inc. | Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase |
US5692337A (en) * | 1995-06-07 | 1997-12-02 | Motz, Jr.; Ronald W. | Collapsible plant shelter |
US5776946A (en) * | 1995-08-28 | 1998-07-07 | Mcgeer; Patrick L. | Peripheral benzodiazepine receptor ligands as antiinflammatory agents |
US6004942A (en) * | 1995-08-30 | 1999-12-21 | The Regents Of The University Of California | Methods for treating arthritis by administering an apoptosis regulator |
US6579854B1 (en) * | 1996-08-14 | 2003-06-17 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
US7351421B2 (en) * | 1996-11-05 | 2008-04-01 | Hsing-Wen Sung | Drug-eluting stent having collagen drug carrier chemically treated with genipin |
PT945445E (pt) * | 1996-12-10 | 2004-01-30 | Zeria Pharm Co Ltd | Derivados de 1,5-benzodiazepina |
US6074859A (en) * | 1997-07-08 | 2000-06-13 | Kikkoman Corporation | Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein |
NZ502362A (en) * | 1997-10-08 | 2001-05-25 | Isotechnika Inc | Deuterated cyclosporine A derivatives and their use as immunomodulating agents |
US6100254A (en) * | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
US6206914B1 (en) * | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
FR2779963A1 (fr) * | 1998-06-22 | 1999-12-24 | Centre Nat Rech Scient | Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer |
US6277844B1 (en) * | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
US20030044776A1 (en) * | 1998-09-25 | 2003-03-06 | James A. Dykens | Compositions and methods for identifying agents that alter mitochondrial permeability transition pores |
FR2785803B1 (fr) * | 1998-11-17 | 2005-03-25 | Sanofi Sa | Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes |
US7175953B2 (en) * | 1999-04-09 | 2007-02-13 | Institute Fuer Diagnostik Forschung | Short-warp peptide-dye conjugate as contrast agent for optical diagnostic |
US20050113460A1 (en) * | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20030119029A1 (en) * | 1999-04-30 | 2003-06-26 | Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
US7276348B2 (en) * | 1999-04-30 | 2007-10-02 | Regents Of The University Of Michigan | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof |
US20060025388A1 (en) * | 1999-04-30 | 2006-02-02 | Glick Gary D | Compositions and methods relating to novel compounds and targets thereof |
DE60007960T2 (de) * | 1999-04-30 | 2004-10-21 | Univ Michigan Ann Arbor | Therapeutische Anwendungen von pro-apoptotischen Benzodiazepinen |
US7144880B2 (en) * | 1999-04-30 | 2006-12-05 | Regents Of The University Of Michigan | Compositions relating to novel compounds and targets thereof |
US20040176358A1 (en) * | 1999-04-30 | 2004-09-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
AU5826100A (en) * | 1999-07-13 | 2001-01-30 | F. Hoffmann-La Roche Ag | Benzazepinones and quinazolines |
US6524623B1 (en) * | 1999-11-12 | 2003-02-25 | Milton Hodosh | Therapeutic compositions and methods of use thereof |
EP1280559B1 (en) * | 2000-05-11 | 2006-03-08 | Eastman Chemical Company | Acylated cyclodextrin guest inclusion complexes |
US20020048566A1 (en) * | 2000-09-14 | 2002-04-25 | El-Deiry Wafik S. | Modulation of cellular apoptosis and methods for treating cancer |
CA2432825A1 (en) * | 2000-12-15 | 2002-06-20 | Emory University | Nonpeptide agonists and antagonists of vasopressin receptors |
EP1392663A2 (fr) * | 2001-06-07 | 2004-03-03 | Neuro3D | Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs |
AU2002332560B2 (en) * | 2001-08-15 | 2006-01-19 | The Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
EP1450901A4 (en) * | 2001-12-10 | 2005-05-25 | Bristol Myers Squibb Co | (1-PHENYL-2-HETEROARYL) ETHYL-GUANIDINE COMPOUNDS AS AN INHIBITORS OF MITOCHONDRIAL F1F0 ATP HYDROLASE |
US20040009972A1 (en) * | 2002-06-17 | 2004-01-15 | Ding Charles Z. | Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase |
US7150433B2 (en) * | 2002-08-16 | 2006-12-19 | Toyota Motor Sales, U.S.A., Inc. | Aircraft bolster trays |
WO2004043362A2 (en) * | 2002-11-06 | 2004-05-27 | Bristol-Myers Squibb Company | Acyl guanidine compounds and use thereof |
US20040087489A1 (en) * | 2002-11-06 | 2004-05-06 | Antonio Ruiz | Compositions and methods for the treatment of mycobacterial infections |
AU2003293405A1 (en) * | 2002-12-03 | 2004-06-23 | Vela Pharmaceuticals, Inc. | Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof |
AU2004255153B2 (en) * | 2003-05-01 | 2007-11-22 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20050272723A1 (en) * | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
US20060052369A1 (en) * | 2004-09-07 | 2006-03-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US7638624B2 (en) * | 2005-01-03 | 2009-12-29 | The Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and derivatives |
BRPI0808653A2 (pt) * | 2007-03-09 | 2014-08-19 | Univ Michigan | Composições e métodos referindo-se a novos compostos e alvos dos mesmos. |
-
2004
- 2004-09-07 US US10/935,333 patent/US20050113460A1/en not_active Abandoned
-
2005
- 2005-09-07 CN CN2005800363803A patent/CN101048162B/zh not_active Expired - Fee Related
- 2005-09-07 EP EP05804417A patent/EP1786429A4/en not_active Withdrawn
- 2005-09-07 AU AU2005282461A patent/AU2005282461C1/en not_active Ceased
- 2005-09-07 JP JP2007531319A patent/JP2008512477A/ja active Pending
- 2005-09-07 US US11/662,103 patent/US20080293700A1/en not_active Abandoned
- 2005-09-07 EP EP11173231A patent/EP2422788A3/en not_active Withdrawn
- 2005-09-07 CA CA002579567A patent/CA2579567A1/en not_active Abandoned
- 2005-09-07 CN CN2011103284209A patent/CN102512424A/zh active Pending
- 2005-09-07 WO PCT/US2005/031942 patent/WO2006029245A2/en active Application Filing
-
2007
- 2007-03-06 IL IL181754A patent/IL181754A0/en unknown
-
2012
- 2012-03-07 IL IL218524A patent/IL218524A0/en unknown
- 2012-06-14 JP JP2012134937A patent/JP2012197305A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2005282461B2 (en) | 2009-11-05 |
US20080293700A1 (en) | 2008-11-27 |
US20050113460A1 (en) | 2005-05-26 |
EP2422788A2 (en) | 2012-02-29 |
WO2006029245A2 (en) | 2006-03-16 |
IL218524A0 (en) | 2012-04-30 |
JP2008512477A (ja) | 2008-04-24 |
JP2012197305A (ja) | 2012-10-18 |
CN101048162B (zh) | 2011-12-28 |
AU2005282461A1 (en) | 2006-03-16 |
CN101048162A (zh) | 2007-10-03 |
EP2422788A3 (en) | 2012-07-11 |
AU2005282461C1 (en) | 2010-06-03 |
CN102512424A (zh) | 2012-06-27 |
EP1786429A2 (en) | 2007-05-23 |
WO2006029245A3 (en) | 2006-12-07 |
CA2579567A1 (en) | 2006-03-16 |
EP1786429A4 (en) | 2009-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL218524A0 (en) | Compositions and methods relating to novel compounds and targets thereof | |
EP1778204A4 (en) | COMPOSITIONS AND METHODS RELATING TO NEW COMPOUNDS AND TARGETS | |
IL195761A0 (en) | Compositions and methods relating to novel compounds and targets thereof | |
EP2139331A4 (en) | COMPOSITIONS AND METHODS FOR NEW CONNECTIONS AND THEIR TARGETS | |
EP1622684A4 (en) | COMPOSITIONS AND METHODS FOR NEW CONNECTIONS AND THEIR TARGETS | |
EP1720957A4 (en) | FERTILIZER COMPOSITIONS | |
EP1718714A4 (en) | COMPOSITIONS CONTAINING A PLOTTER | |
ZA200904425B (en) | Nemathical compositions | |
ZA200701558B (en) | Improvements in or relating to organic compositions | |
EP1763346A4 (en) | COMPOSITION AND METHODS RELATING TO INHIBITORS OF PYRIMIDINE SYNTHESIS | |
GB0405033D0 (en) | Novel pharmaceutical compositions | |
GB0405406D0 (en) | Anti-vaginitis compositions | |
GB0406378D0 (en) | Novel pharmaceutical compositions | |
GB0411205D0 (en) | Improvements in or relating to compositions | |
GB0406380D0 (en) | Novel pharmaceutical compositions | |
IL186606A0 (en) | Compositions and uses of amooranin compounds | |
GB0412584D0 (en) | Composition of matter | |
ZA200701197B (en) | Compositions | |
GB0427308D0 (en) | Improvements relating to surfactant compositions | |
GB0410140D0 (en) | Compositions | |
EP1744755A4 (en) | COMPOUNDS AND COMPOSITIONS AS CATHEPSIN S HEMMER | |
GB0424051D0 (en) | Compounds and compositions | |
GB0424013D0 (en) | Improvements in or relating to compositions | |
GB0424012D0 (en) | Improvements in or relating to compositions | |
GB0425445D0 (en) | Novel compositions |